Treatment and Prevention of Anemia With Ferrous Sulfate Plus Folic Acid in Children in Goiania - Goias, Brazil

NCT ID: NCT00701246

Last Updated: 2014-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

196 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Iron deficiency anemia is the most common nutritional problem in the world.

The objectives of this study are:

* to evaluate the prevalence of anemia in children from 6 to 24 months of age and the therapeutic and prophylactic response to ferrous sulfate plus folic acid on hemoglobin levels.
* to compare the effect of folic acid supplementation with ferrous sulfate on the linear and weight growth of anemic and non-anemic

Study hypothesis:

* The ferrous sulfate plus folic acid can improve the response on hemoglobin levels.
* The folic acid supplementation with ferrous sulfate have effect on the linear and weight growth of anemic and non-anemic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose

The objective of this study were:

* to assess the prevalence of anemia and the therapeutic and prophylactic response to ferrous sulfate and folic acid.
* to compare the effect of folic acid supplementation with ferrous sulfate on the linear and weight growth of anemic and non-anemic.

A double-blind, randomized, controlled clinical trial was conducted with 196 children 6 to 24 months of age enrolled in municipal daycare centers in Goiânia, Goias State, Brazil. The children were assigned to two treatment groups that received a daily dose (5 times a week) of either 4.2mg/kg/day of ferrous sulfate + folic acid (50μg) or 4.2mg/kg/day of ferrous sulfate + folic acid placebo. One of the prevention groups received 1.4mg/kg/day of ferrous sulfate + folic acid (50μg/day) and the other 1.4mg/kg/day of ferrous sulfate + folic acid placebo. Supplementation lasted approximately three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I

I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)

Group Type EXPERIMENTAL

ferrous sulfate

Intervention Type DRUG

folic acid

Intervention Type DRUG

II

II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.

Group Type PLACEBO_COMPARATOR

ferrous sulfate

Intervention Type DRUG

placebo (folic acid)

Intervention Type DRUG

III

Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid

Group Type EXPERIMENTAL

ferrous sulfate

Intervention Type DRUG

folic acid

Intervention Type DRUG

IV

1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.

Group Type PLACEBO_COMPARATOR

ferrous sulfate

Intervention Type DRUG

placebo (folic acid)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ferrous sulfate

Intervention Type DRUG

folic acid

Intervention Type DRUG

placebo (folic acid)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* from 6 to 24 months
* born at term
* non-twins
* with parental approval for participation in the study
* attending municipal daycare centers with mor than four children each

Exclusion Criteria

* Children with special needs
* low birth weight (\<2.500g)
* with growth-impairing heart diseases
* neurological syndromes
* sickle-cell anemia
* sickle-cell trait
* under treatment for anemia at the time of the first interview or screening performed by the pediatrician
* those no longer attending the daycare center
* the clinical trial excluded children with hemoglobin \>=7 amd \<=8g/dL.
* For the second objective: incomplete anthropometric surveys
Minimum Eligible Age

6 Months

Maximum Eligible Age

24 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Federal University of São Paulo

OTHER

Sponsor Role collaborator

Ministry of Health, Brazil

OTHER_GOV

Sponsor Role collaborator

Goiania Municipal Health Department

UNKNOWN

Sponsor Role collaborator

Universidade Federal de Goias

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maria Claret Costa Monteiro Hadler

PhD.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maria Claret CM Hadler, PhD Sciences

Role: PRINCIPAL_INVESTIGATOR

Universidade Federal de Goias

Dirce M Sigulem, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Federal University of São Paulo

Maria de Fátima C Alves, PhD

Role: PRINCIPAL_INVESTIGATOR

Universidade Federal de Goias

Vinícius M Torres, MD

Role: PRINCIPAL_INVESTIGATOR

Vila São José Bento Cotolengo

Daniela AM Dias, MSc.

Role: PRINCIPAL_INVESTIGATOR

Faculty of Nutrition of Federal University of Goias

Andréa Sugai, PhD.

Role: PRINCIPAL_INVESTIGATOR

Faculty of Nutrition - Federal University of Goias

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Universidade Federal de Goias

Goiânia, Goiás, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Wieringa FT, Dijkhuizen MA, van der Ven-Jongekrijg J, West CE, Muhilal, van der Meer JW. Micronutrient deficiency and supplementation in Indonesian infants. Effects on immune function. Adv Exp Med Biol. 2003;531:369-77. doi: 10.1007/978-1-4615-0059-9_31. No abstract available.

Reference Type BACKGROUND
PMID: 12916807 (View on PubMed)

Allen LH, Rosado JL, Casterline JE, Lopez P, Munoz E, Garcia OP, Martinez H. Lack of hemoglobin response to iron supplementation in anemic mexican preschoolers with multiple micronutrient deficiencies. Am J Clin Nutr. 2000 Jun;71(6):1485-94. doi: 10.1093/ajcn/71.6.1485.

Reference Type BACKGROUND
PMID: 10837289 (View on PubMed)

Hadler MC, Juliano Y, Sigulem DM. [Anemia in infancy: etiology and prevalence]. J Pediatr (Rio J). 2002 Jul-Aug;78(4):321-6. Portuguese.

Reference Type BACKGROUND
PMID: 14647764 (View on PubMed)

Hadler MC, Colugnati FA, Sigulem DM. Risks of anemia in infants according to dietary iron density and weight gain rate. Prev Med. 2004 Oct;39(4):713-21. doi: 10.1016/j.ypmed.2004.02.040.

Reference Type BACKGROUND
PMID: 15351537 (View on PubMed)

Geltman PL, Meyers AF, Mehta SD, Brugnara C, Villon I, Wu YA, Bauchner H. Daily multivitamins with iron to prevent anemia in high-risk infants: a randomized clinical trial. Pediatrics. 2004 Jul;114(1):86-93. doi: 10.1542/peds.114.1.86.

Reference Type BACKGROUND
PMID: 15231912 (View on PubMed)

Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, Dhingra U, Kabole I, Deb S, Othman MK, Kabole FM. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet. 2006 Jan 14;367(9505):133-43. doi: 10.1016/S0140-6736(06)67962-2.

Reference Type BACKGROUND
PMID: 16413877 (View on PubMed)

Hadler MC, Sigulem DM, Alves Mde F, Torres VM. Treatment and prevention of anemia with ferrous sulfate plus folic acid in children attending daycare centers in Goiania, Goias State, Brazil: a randomized controlled trial. Cad Saude Publica. 2008;24 Suppl 2:S259-71. doi: 10.1590/s0102-311x2008001400011.

Reference Type RESULT
PMID: 18670706 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FANUT 302004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.